Related Experiment Video
Updated: Jun 21, 2026
08:52
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
Published on: February 5, 2021
[Mucosal healing in Crohn disease]
Lukasz Jałocha1, Stanisław Wojtuń, Przemysław Dyrla
1Military Institute of Health Services in Warsaw, Department of Gastroenterology, Central Clinical Hospital of the Ministry of National Defense. ljalocha@yahoo.com
Summary
Achieving clinical remission and complete mucosal healing is crucial for effective Crohn disease treatment. Early, aggressive therapies like the top-down approach may improve outcomes compared to traditional steroid use, but require further clinical validation.
Area of Science:
- Gastroenterology and immunology, focusing on inflammatory bowel diseases.
Context:
- Crohn disease management presents significant clinical challenges.
- Current treatment paradigms often prioritize clinical remission over complete mucosal healing.
Purpose:
- To evaluate the significance of mucosal healing alongside clinical remission in Crohn disease.
- To assess the efficacy of different therapeutic strategies, including immunosuppressants and biologics, on mucosal healing.
Summary:
- Effective Crohn disease treatment necessitates achieving both clinical remission and complete mucosal healing.
- Immunosuppressants (azathioprine, 6-mercaptopurine, methotrexate) and biological therapies are key for mucosal healing.
- The timing and selection of medical treatment, particularly aggressive 'top-down' regimens, appear more successful than conventional steroid-based approaches.
Impact:
- Highlights the importance of mucosal healing as a treatment goal in Crohn disease.
- Suggests that early, aggressive treatment strategies may offer superior outcomes for mucosal healing.
- Emphasizes the need for further clinical trials to validate these findings and optimize Crohn disease management.
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:21Inflammatory Bowel Disease V: Surgical Management
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...